Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
Date:3/1/2010

NANJING, China, March 1 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2009, on Tuesday, March 16, 2010, before the market opens in the United States. Simcere's Chief Executive Officer, Jinsheng Ren, and Chief Financial Officer, Frank Zhigang Zhao, will host an earnings conference call on the same day, at 8 a.m. ET (Tuesday, March 16, at 8 p.m. Beijing/Hong Kong time).

    To access the conference call, please dial:
    United States toll-free:    +1.800.901.5213
    International:              +1.617.786.2962
    North China toll-free:      10.800.152.1490
    South China toll-free:      10.800.130.0399
    China toll free / Netcom:   10 800 852 1490
    Hong Kong:                  +852.3002.1672

Please ask to be connected to Q4 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 65611658.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .


    Following the earnings conference call, an archive of the call will be
available by dialing:

    United States toll-free:   +1.888.286.8010
    International:             +1.617.801.6888

The passcode for replay participants is: 88577131. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

SOURCE Simcere Pharmaceutical Group

Back to top

RELATED LINKS
http://www.simcere.com

'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):